Evidence map›Paper›PMID 42889246›Full record

ArticleFrontiers in medicine2026

Tranexamic acid use and progression to clinically important bleeding in critically ill patients with non-clinically important non-variceal upper gastrointestinal bleeding: a retrospective cohort study.

Ji Luo, Zheng Lei, Yuanjun Zhang, Zhiwei Yao, Xin Fu, Luping Wang, Shucheng Zhao, Jing Yang, Bo Wang, Hao Yang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ji Luo *Department of Critical Care Medicine, West China Hospital of Sichuan University-Ziyang Hospital, Ziyang Central Hospital, Ziyang, Sichuan, China.
Zheng Lei *Department of Critical Care Medicine, West China Hospital of Sichuan University-Ziyang Hospital, Ziyang Central Hospital, Ziyang, Sichuan, China.
Yuanjun Zhang *Department of Critical Care Medicine, West China Hospital of Sichuan University-Ziyang Hospital, Ziyang Central Hospital, Ziyang, Sichuan, China.
Zhiwei YaoDepartment of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xin FuDepartment of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Luping WangDepartment of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Shucheng ZhaoDepartment of Critical Care Medicine, West China Hospital of Sichuan University-Ziyang Hospital, Ziyang Central Hospital, Ziyang, Sichuan, China.
Jing YangDepartment of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Bo WangDepartment of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Hao YangDepartment of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Qin WuDepartment of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tranexamic acid (TXA) is widely used to reduce bleeding in perioperative and hemorrhagic conditions, but its role in upper gastrointestinal bleeding (UGIB) remains controversial. This single-center retrospective cohort study evaluated whether TXA use was associated with reduced progression to clinically important gastrointestinal bleeding (GIB) in critically ill patients with non-clinically important non-variceal UGIB. Adult ICU patients who developed non-clinically important non-variceal UGIB between 2018 and 2022 were included. Among them, 154 patients receiving TXA within 24 h after bleeding onset (mean duration 1.71 ± 1.42 days; mean total dose 2.12 ± 2.36 g) were compared with 1,660 patients who received neither TXA nor other hemostatic agents. After propensity score matching, 154 matched pairs were analyzed. Progression to clinically important GIB did not differ significantly between the TXA and non- TXA groups before matching (5.8% vs. 5.7%;

Indexed as

clinically important gastrointestinal bleedingin-hospital mortalitynon-clinically important nonvariceal upper gastrointestinal bleedingthrombotictranexamic acid

Identifiers

PMID42889246
PMCPMC13668849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.